Johnson & Johnson (JNJ) IMAAVY Data Puts Its Undervalued Narrative Back In Focus

Johnson & Johnson (JNJ) is back in focus after new IMAAVY data in generalized myasthenia gravis, giving investors fresh insight into how its immunology pipeline might complement the stock’s recent double digit one year return. Despite the IMAAVY update and a string of recent drug data releases across immunology, oncology and neuroscience, Johnson & Johnson’s share price has eased in the short term, with the stock down 4.4% over the past week and 4.6% over the past month. However, a 24.8% year...